九州大学 研究者情報
研究者情報 (研究者の方へ)入力に際してお困りですか?
基本情報 研究活動 教育活動 社会活動 病院臨床活動
草場 仁志(くさば ひとし) データ更新日:2021.10.25

准教授 /  医学研究院 臨床医学部門 九州大学病院 血液・腫瘍内科


主な研究テーマ
固形癌における腫瘍循環器学(血管障害, 心筋障害)
キーワード:腫瘍循環器学
2017.04~2021.10.
がん幹細胞、薬剤耐性、細胞内シグナル伝達、がんの転移制御
キーワード:がん、薬剤耐性、細胞内シグナル伝達、がんの転移制御
2005.04.
研究業績
主要著書
1. 草場 仁志, 新臨床腫瘍学 改訂3版, 2013.04.
主要原著論文
1. Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M, Komoda M, Kono M, Fukata M, Arita T, Esaki T, Akashi K, Baba E. , Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. , Gastric Cancer, 22, 5, 988-998, 2019.04.
2. Kumagai H, Kusaba H, Yamanaka T, Nio K, Inadomi K, Takayoshi K, Ito M, Tamura S, Makiyama A, Makiyama C, Hirano G, Shibata Y, Shirakawa T, Mitsugi K, Ariyama H, Esaki T, Akashi K, Baba E., A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy. , Medicine, 97, 25, e11042, 2018.05.
3. K Nio, hitoshi kusaba, Ariyama Hiroshi, Eishi Baba, Shuji Arita, koichi akashi, Kenichi Kohashi, Esaki T, Makiyama A, Hirano G, Mitsugi K, Kajitani T, Tamura S, Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy., Cancer Chemotherapy and Pharmacology, 75, 4, 829-835, 2015.04.
4. Hironaka S, Tsubosa Y, Mizusawa J, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Ura T, hitoshi kusaba, Nakamura T, Kitagawa Y, Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). , Cancer Sci , 105, 1189-1195, 2014.09.
5. 草場 仁志, 江崎 泰斗, Junji Kishimoto, 内野 慶太, Shuji Arita, 三ツ木 健二, Koichi Akashi, Eishi Baba, Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. , Cancer Chemother Pharmacol., 71, 1, 29-34, 2013.01, The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer. However, the safety and efficacy of bevacizumab (BV) to combine with irinotecan and S-1 has not been determined. The aim of the study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of BV combined with irinotecan plus S-1, and to observe the safety and efficacy of this regimen as second-line chemotherapy in patients with advanced colorectal cancer.
METHODS:This study initially had been planned as a phase I/II study. Eighty mg/m(2) of irinotecan on days 1 and 8, 80 mg/m(2) of S-1 for 14 consecutive days, and two doses of BV (Level 1; 10 mg/kg, Level -1; 7.5 mg/kg) were administered on day 1 every 3 weeks.
RESULTS:Fourteen patients were enrolled in phase I of the study between January 2008 and September 2010. Dose-limiting toxicities were diarrhea, abdominal pain, and infection. The MTD and RD of BV were determined to be 10 mg/kg and 7.5 mg/kg, respectively. The main adverse events were leukopenia, anorexia, and diarrhea. There were no treatment-related deaths. An independent review committee was scheduled to evaluate safety in phase I, but this trial closed early due to toxicity.
CONCLUSIONS:This study identified the risk of gastrointestinal toxicity with the combination of irinotecan, S-1 and BV as second-line chemotherapy in patients with advanced colorectal cancer..
6. Uchino K, Hirano G, Hirahashi M, Isobe T, Shirakawa T, Kusaba H, Baba E, Tsuneyoshi M, Akashi K. , Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells. , Exp Cell Res., 318, 15, 1799-1807, 2012.05.
7. Eishi Baba • Hiromitsu Fujishima • Akitaka Makiyama • Keita Uchino • Risa Tanaka • Taito Esaki •Hitoshi Kusaba • Kenji Mitsugi • Shuji Nakano • Koichi Akashi. , Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patient. , Advances in Therapy, 1, 1-10, 2012.01.
8. Keita Uchino, Hitoshi Kusaba, Junji Kishimoto, Hiroshi Mitsuyasu, Hiroaki Kawasaki, Eishi Baba, and Koichi Akashi., Validation of Hospital Anxiety and Depression scale as a screening tool for Psychological distress in advanced cancer patients undergoing chemotherapy., Palliative Care Research, 6, 2, 150-156, 2011.10.
9. Hitoshi Kusaba, Taito Esaki, Kitaro Futami, Sinnosuke Tanaka, Hiromitsu Fujishima, Kenji Mitsugi, Kenji Sakai, Hiroshi Ariyama, Risa Tanaka, Naoko Kinugawa, Takashi Ueki, Rhuichi Mibu, Eishi Baba, Shuji Nakano, Koichi Akashi, Phase I/II study of a 3-week cycle Irinotecan and S-1 in patients with advanced colorectal cancer., Cancer Science, 101, 12, 2591-5, 2010.12.
10. Kusaba H, Ghosh P, Derin R, Buchholz M, Sasaki C, Madara K, Longo DL., IL12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR)., J Biol Chem, 280(2),1037-1043, 2005.01.
11. H.Kusab, T.Tamura, T.Shimoyama,Y.Akiyama,N.Yamamoto,I.Sekine,H.Kunitoh,Y.Ohe,T.Kodama,N.Saijo, Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer., Jpn.J.Clinic.Oncology., 32(2), 43-47, 2002.01.
12. J.Nagayama,Y.Tada,T.Harada,H.Kusaba,A.Klue,K.Oshima,M.Kuwano,M.Wada, Retrovirus insertion and transcriptional activation of the multidrug-resistance gene in leukemias treated by a chemotherapeutic agent in vivo., Blood, 10.1182/blood.V97.3.759, 97, 3, 759-766, 97(3),759-766, 2001.01.
13. H.Kusaba,K.Kohno,K.Asakuno,M.Kuwano,K.Okumura,E.D.Green,D.Schlessinger,M.Wada, Functional expression of yeast artificial chromosome- human multidrug resistance
genes in mouse cells., Genome Research, 10.1101/gr.5.3.245, 5, 3, 245-258, 5(3),245-258, 1995.01.
主要総説, 論評, 解説, 書評, 報告書等
主要学会発表等
1. mamoru tanaka, hitoshi kusaba, Eishi Baba, koichi akashi, Exploratory analysis of a prognosis predictiveformulafor metastatic colorectal cancer treated with chemotherapy.

, American Society of Clinical Oncology, Gastrointestinal cancer, 2015.01.
2. 草場 仁志, 癌患者における精神症状の発現を予測するスクリーニング法の開発, 第19回 ヘルスリサーチフォーラム.
3. Tsuyoshi Shirakawa, Shingo Tamura, Masato Komoda, Taichi Isobe, Shigeo Takaishi, Hitoshi Kusaba, Eishi Baba, Koichi Akashi. , Breast cancer stem cells selected by bone marrow microenvironment highly express
Notch1, CD44 and CD49f.
, 70th Annual Meeting of the Japan Cancer Association, 2011.10.
4. 草場仁志, 江崎泰斗, 藤本千夏, 在田修二, 牧山明資, 内野慶太, 磯部大地,白川剛, 薦田正人, 岸本淳司, 三ツ木健二, 赤司浩一, 馬場英司, 進行・再発結腸・直腸癌に対する二次治療としてのCPT-11+TS-1+BV併用第Ⅰ相臨床試験

, 第9回日本臨床腫瘍学会総会, 2011.07.
5. K. Uchino, G. Hirano, M. Hirahashi, T. Shirakawa, H. Kusaba, M. Tsuneyoshi, E. Baba, K. Akashi, Human Nanog P8 promotes the proliferation of gastrointestinal cancer cells. , 34th European Society of Medical Oncology Congress, 2009.09.
学会活動
所属学会名
日本腫瘍循環器学会
日本がん分子標的治療学会
日本緩和医療学会
ASCO
日本消化器病学会
日本内科学会
日本癌治療学会
日本臨床腫瘍学会
学協会役員等への就任
2015.04~2017.03, 日本分子標的治療学会, 評議員.
2009.04~2017.03, 日本臨床腫瘍学会, 専門医委員.
2006.04~2017.03, 日本臨床腫瘍学会, 評議員.
学会大会・会議・シンポジウム等における役割
2021.04.09~2021.04.11, 第118回 日本内科学会学術総会・講演会, 事務局長.
2021.02.18~2021.02.21, 第18回日本臨床腫瘍学会総会, 座長(Chairmanship).
2018.07.19~2015.07.21, 第16回日本臨床腫瘍学会総会, 座長(Chairmanship).
2017.07.27~2015.07.29, 第15回日本臨床腫瘍学会総会, 座長(Chairmanship).
2015.07.16~2015.07.18, 第13回日本臨床腫瘍学会総会, 座長(Chairmanship).
2014.07.17~2014.07.19, 第12回日本臨床腫瘍学会学術集会総会, 座長.
2012.07.26~2011.07.28, 第10回日本臨床腫瘍学会学術集会総会, 座長.
2008.03~2008.03, 日本臨床腫瘍学会, 事務局長.
2011.07.20~2011.07.23, 日本臨床腫瘍学会学術集会総会, ワークショップ座長.
その他の研究活動
海外渡航状況, 海外での教育研究歴
American Society of Clinical Oncolog-GI, UnitedStatesofAmerica, 2015.01~2015.01.
American Society of Clinical Oncology, UnitedStatesofAmerica, 2013.06~2013.06.
American Society of Clinical Oncology, UnitedStatesofAmerica, 2012.06~2013.06.
National Institute of Health, UnitedStatesofAmerica, 2001.09~2004.06.

九大関連コンテンツ

pure2017年10月2日から、「九州大学研究者情報」を補完するデータベースとして、Elsevier社の「Pure」による研究業績の公開を開始しました。
 
 
九州大学知的財産本部「九州大学Seeds集」